Patheon — Q1 2012 Earnings Presentation
18 slides from Patheon's earnings presentation, Mar 9, 2012
Slide 1: Fiscal 2012 First Quarter Earnings
Patheon Fiscal 2012 First Quarter Earnings Friday, March 9, 2012 Exhibit 99.2
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements or information which reflect our expectations regarding possible events, conditions, our future growth, results of operations, performance, and business prospects and opportunities. All statements, other than statements
Slide 3: Agenda
Agenda • Financial results • Transformation update • Q&A
Slide 4: Financial Overview (U.S. GAAP)
Financial Overview (U.S. GAAP) Associated with cancellation of a manufacturing agreement 7.8% revenue growth excluding the benefit from contract cancellation REVENUE (U.S. $ in millions) Reported revenue including the benefit from the contract cancellation
Slide 5: Financial Overview (U.S. GAAP)
Financial Overview (U.S. GAAP) (U.S.$ in millions) Reported Adjusted EBITDA includes the benefit from the contract cancellation and the additional expense from consulting fees
Slide 6: Summary Balance Sheet and Cash Flow (U.S. GAAP)
Summary Balance Sheet and Cash Flow (U.S. GAAP) (U.S.$ in millions) 2012 - Q1 2011 - Q4 Cash and cash equivalents 32.5 33.4 A/R 125.0 158.0 Inventory 83.0 81.8 Capital assets 458.6 474.2 Total assets 784.1 824.6 AP and accrued liabilities 176.8 181.5 Total debt 284.0 287.3 Total deferred revenue 38.
Slide 7: Our Situation Today
Our Situation Today #2 market share in CMO #1 market share in PDS Below average financial performance Good reputation with customers but uneven operational performance
Slide 8: Our Goal
Our Goal #1 market share in PDS #1 market share in CMO, with above market growth Top quartile financial performance and improved profitability Best reputation in quality, delivery and cost competitiveness
Slide 9: Five Commitments
Five Commitments Provide the industry’s leading customer experience. Operate our business in a disciplined, responsible, and ethical fashion such that our shareholders will appreciate superior returns over time. Provide the best technical and scientific solutions to solve difficult development probl
Slide 10: Strategy: Strengthen core, sell differently, enter adjacencies, drive consolidation
Strategy Strengthen core operations Sell business differently Enter logical adjacencies Drive industry consolidation Our strategy boils down to improving what we do, how we sell, then grow our business into adjacencies inorganically
Slide 11: Strategy – Strengthen the Core
Strategy – Strengthen the Core Strengthen core operations Operational excellence roll-out across the organization Increasing efficiency, productivity in our sites - Underway in the U.S. and Canada - Beginning in Europe and Puerto Rico - Centers of Excellence roll-out by site - Expanded the program i
Slide 12: Strategy – Sell the Business Differently
Strategy – Sell the Business Differently Sell business differently Solution and “targeted” selling build on our strengths Recent successes - SoluPath ™ - Sterile back-up supply - End-to-end solutions provider from PDS to CMO - Strategic partnerships
Slide 13: Strategy – Enter Logical Adjacencies
Enter logical adjacencies Strategy – Enter Local Adjacencies Four core dimensions - Value Chain • Early development • Supply chain integration - New capabilities – P-Gels™ and SoluPath™ - Technology – proprietary drug delivery - Geography – emerging markets
Slide 14: P-Gels™
P-Gels™ • Prescription soft gels for North America, Europe and Asia – mutually exclusive for Rx soft gels in the territory – Development services – Cincinnati or Barranquilla – Commercial manufacturing – Barranquilla • Joint selling and execution by Patheon and for our joint opportunities – will be
Slide 15: Outcomes
Outcomes Provide the industry’s leading customer experience. Operate our business in a disciplined, responsible, and ethical fashion such that our shareholders will appreciate superior returns over time. Provide the best technical and scientific solutions to solve difficult development problems and
Slide 16: Summary
Summary • Underlying revenues are growing • Transformation activities are on track • Balance sheet and liquidity are good
Slide 17: Q&A
Q&A
Slide 18: Appendix: Adjusted EBITDA Bridge (US GAAP)
Appendix Adjusted EBITDA Bridge (US GAAP) (unaudited) Q1 2010 Q2 2010 Q3 2010 Q4 2010 Q1 2011 Q2 2011 Q3 2011 Q4 2011 Q1 2012 (in millions of U.S. dollars) $ $ $ $ $ $ $ $ $ Adjusted EBITDA 8.3 26.0 20.4 26.2 28.7 12.9 10.3 14.5 (9.2) Depreciation and amortization (14.9) (13.5) (12.6) (14.6) (14.9)